Mark E. Dmytruk - 06 Mar 2025 Form 4 Insider Report for Ginkgo Bioworks Holdings, Inc. (DNA)

Role
Chief Financial Officer
Signature
/s/ Karen Tepichin, Attorney-in-Fact
Issuer symbol
DNA
Transactions as of
06 Mar 2025
Net transactions value
$0
Form type
4
Filing time
10 Mar 2025, 17:01:45 UTC
Previous filing
06 Mar 2025
Next filing
17 Mar 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction DNA Restricted Stock Units Award +4,245 4,245 06 Mar 2025 Class A Common Stock 4,245 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock.
F2 The RSUs vest as follows: 25% on April 16, 2025; 25% on July 16, 2025; 25% on October 16, 2025; and 25% on January 16, 2026.

Remarks:

Chief Financial Officer